November 12, 2024 | In this episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, speaks with Anthony Tolcher, M.D., FRCPC, cofounder of NEXT Oncology, about antibody drug conjugates (ADCs) including the role of the bystander effect, approaching targets in oncology, dual-payload tech…

October 15, 2024 | In this month’s episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, and John Lambert, PhD, consultant, about antibody drug conjugates (ADCs) then, now, and beyond. Lambert shares his experiences from his decades-long career at ImmunoGen, why ADCs are more success…

September 10, 2024 | In this episode of The Chain, host Nimish Gera speaks with Tariq Ghayur, founder of FairJourney Biologics (and a fellow host of the podcast), about the current renaissance of bispecifics and ADCs, the impact of AI in pharmaceuticals, and what to watch out for in the biopharma space in the next few years. Ghayur also shares his …

In this episode of The Chain, host Nimish Gera, Ph.D., vice president of biologics at Mythic Therapeutics, speaks with Peyton Greenside, CSO and co-founder of BigHat Biosciences, about the role of AI and machine learning in antibody engineering and targeting complex modalities, including bispecifics and ADCs. Greenside also discusses the work her o…

In this episode of The Chain, host Brandon DeKosky, associate professor at MIT, speaks with Andrew Kruse, PhD, professor of biological chemistry and molecular pharmacology at Harvard University, about protein signaling and structural biology. Kruse explains what exactly bias signaling is and discusses the problems he and his team are working to res…

his special episode of The Chain features a panel of industry experts who discussed AI and ML in antibody discovery and engineering at this year’s PEGS Boston event. Peter Tessier, professor at the University of Michigan; Andrew Bradbury, CSO at Specifica; Andrew Waight, Senior Director of Machine Learning, Discovery Biologics & Protein Sciences at…

In this episode of The Chain, host Tariq Ghayur, PhD, consultant and entrepreneur in residence, FairJourney Biologics, speaks with Tomoyuki Igawa, PhD, chief executive officer, Chugai Pharmabody Research in Singapore, about his 20+ years of experience in drug discovery and development. Igawa possesses a unique perspective that has allowed him and h…

This month The Chain shares a recent episode of the Lab Rats to Unicorns podcast. Lab Rats to Unicorns, hosted by John Flavin, aims to demystify the process of creating a great company in the life sciences, biotech, medtech, clean energy, and beyond. In this episode, Flavin speaks with Lesley Millar-Nicholson, executive director of MIT’s Technology…

In this month’s episode of The Chain, host Ben Hackel, professor of Chemical Engineering & Materials Science at the University of Minnesota, speaks with Gabriel Rocklin, assistant professor of Pharmacology at Northwestern University, about two recently published papers from Rocklin’s lab: one on advancing the ability to design challenging typologie…

How does one maintain innovation in the antibody industry? In this episode of The Chain, host Tariq Ghayur, PhD, consultant and entrepreneur in residence, FairJourney Biologics, talks with Janine Schuurman, PhD, president of The Antibody Society, independent biotech consultant and founder of Lust for Life Sciences, about her inspiration to get into…

Bispecific antibody drug conjugates (ADCs) have been undergoing a renaissance in recent years. As big pharma continues to express more interest, what can the field expect for the future of ADCs? In this episode of The Chain, Nimish Gera, Ph. D., Vice President of Biologics of Mythic Therapeutics, speaks with Rakesh Dixit, Ph. D., President & CEO of…

What can we expect from GPCRs in antibodies and biologics? In this episode of The Chain, host Rajesh Sundaresan, PhD, Scientific Leader and GSK Fellow of Protein Cell and Structural Sciences at GlaxoSmithKline, speaks with Thomas P. Sakmar, MD, Professor of Chemical Biology at Rockefeller University, about the history of GPCRs and various subunits,…

In this episode of The Chain, Richard Bonneau, PhD, and Marcel Hop, PhD, of Genentech interview Tala Fakhouri, PhD, of the FDA on her thoughts on the discussion paper, “Using Artificial Intelligence & Machine Learning in the Development of Drug & Biologic Products” and the evolving role of AI/ML to create models and inform decisions in biopharmaceu…

With the whirlwind development of AI, it can be difficult to keep track of its uses in both research and the market. In this episode of The Chain podcast, host Ben Hackel, Professor of Chemical Engineering & Materials Science at the University of Minnesota, speaks with Enkelejda “Ledi” Miho, Professor of Digital Life Sciences at the University of A…

What is the first step of getting into biotech? How do you make real progress in research? In honor of Ovarian Cancer Awareness Month, host Nimish Gera discusses these topics and more with Jonathan Sockolosky, PhD, Director of CSO Partner Team at Curie.Bio, in this special episode of The Chain. Jonathan details how he got started in biotech, what i…

In this episode of The Chain, Brandon Dekosky, Associate Professor at MIT, speaks with Adrian Bot, Founding Chief Scientific Officer and Executive Vice President of R&D at Capstan Therapeutics, about his experiences in leadership roles, his scientific journey, and how he started work on immunotherapy for cancer. Bot also shares what it's like to be…

In this special episode of The Chain, G. Jonah Rainey, Senior Director of Protein Engineering at Eli Lilly and Company, hosts a panel at PEGS 2023 to discuss strategies to engineer parameters for solid tumor-targeting T-cell-engagers. Guests Stephen J. Demarest from Tentarix Biotherapeutics, Michelle Morrow from F-Star Therapeutics, Inc., and Dario…

In this month’s episode of The Chain, Greg M. Thurber, associate professor of chemical engineering and biomedical engineering at the University of Michigan, sits with moderator Nimish Gera, vice president of biologics at Mythic Therapeutics, to talk about the development of antibody drug conjugates (ADCs). Thurber details the history of ADCs and th…

Kyron.Bio is revolutionizing drug production with its Next Generation Bioproduction Platform that will make the production of therapeutics easier, cheaper and faster. Voldborg and McLaughlin talk about their shared vision for using synthetic biology to improve the production of therapeutic proteins. Kyron.Bio: https://kyron.bio/…

In this month’s episode of the Chain, guest Peter Tessier, Albert M. Mattocks pharmaceutical sciences and chemical engineering professor at the University of Michigan, speaks with moderator Tariq Ghayur, scientific advisor and entrepreneur in residence at FairJourney Biologics, about expediting the developability of antibodies. He discusses the cha…

Dr. Andrew Anzalone, head of the Prime Editing Platform and scientific co-founder at Prime Medicine, is the winner of the PEGS Boston 2023 Young Scientist Keynote. He was invited to sit down with Brandon DeKosky, assistant professor of chemical engineering at MIT, to discuss prime editing and its precision in treating inherited genetic mutations. A…

Jan Terje Andersen, professor of biomedical innovation in the Department of Pharmacology at the University of Oslo and research group leader in the Department of Immunology at the Oslo University Hospital, has spent nearly two decades studying neonatal Fc receptors (FcRns) and their interactions with prominent blood proteins albumin and IgG. He sit…

In this month’s episode of the Chain, Jim Wells, professor of pharmaceutical chemistry and cellular and molecular pharmacology at the University of California, San Francisco, sits down with moderator Ben Hackel, associate professor of chemical engineering and materials science at the University of Minnesota, to discuss Wells’ work in advancing targ…

Over the last two decades, cryogenic electron microscopy (cryo-EM) has transformed from what Dr. Andrew Ward calls the “outcast of structural biology” to one of the most promising technologies in the field. Ward, professor of integrative structural and computational biology at Scripps Research Institute, speaks with moderator Brandon DeKosky, assis…

Dame Jane Osbourn, chief scientific officer at Alchemab Therapeutics, speaks with Ahuva Nissim, antibody and therapeutic engineering professor at Queen Mary University of London William Harvey Research Institute, about the career path that took her from studying molecular biology and building human phage libraries to developing therapeutics with co…

Charlotte Deane, professor of structural bioinformatics at the University of Oxford and upcoming speaker at the 14th Annual PEGS Europe Conference in Barcelona, joins moderator Brandon DeKosky, assistant professor of chemical engineering at the Massachusetts Institute of Technology, to discuss the use of machine learning in antibody structure predi…

After over 25 years as an intellectual property (IP) attorney, Jane Remillard, Nelson Mullins patents and biotechnology IP senior partner, is well-versed in navigating drug development and antibody patent law. In this episode, Remillard speaks with moderator Nimish Gera, Mythic Therapeutics vice president of biologics, about the intersection betwee…

Dr. Nimish Gera, Head of Biologics at Mythic Therapeutics, sits down with Christina Lingham, Executive Director of Conferences and Fellow at Cambridge Healthtech Institute, in this Episode of the Chain to talk about how the developability of bispecific antibodies topic came about, how the field is changing, new bispecific molecules coming through t…

Rene Hoet is working for over 20 years in Biotech and Pharma Industry focusing on Antibody Research and development. Since April 1 2021 Rene works as Chief Scientific Officer at Montis Biosciences, Leuven, Belgium to develop the next generation Immuno-Oncology drugs using a novel approach interfering in the Tumor Endothelial Cell and Perivascular M…

A University of Alabama Birmingham researcher was frustrated with inconsistent solutions and processes for purifying unique proteins and set out to develop a new approach for high throughput protein purification. Thus was the seed idea for TriAltus Bioscience, which aims to bring protein purification technology from the research bench to the produc…

The Chain looks back to earlier this year when researchers virtually convened on the one-year anniversary of the first documented case of COVID-19 in the United States. This episode brings you a panel discussion from PepTalk Protein Science and Production Week, moderated by Karla Satchell, PhD, Professor of Microbiology and Co-Director of the Cente…

Nancy Sajjadi joins The Chain to share her quality control knowledge and experience of adopting a quality-by-design approach for assays. We discuss how the focus of her QC work has changed through the years, and what kind of challenges she foresees as the cell and gene therapy fields move forward. Ms. Sajjadi talks about consulting with clients who…

In this episode, Dr. Willem Overwijk returns for a conversation with Dr. Éric Vivier. Dr. Vivier is a professor of immunology at Aix-Marseille and a hospital practitioner at Marseille Public University Hospital. Éric Vivier is also the Chief Scientific Officer at Innate Pharma, a clinical-stage biotech company that creates novel antibodies that act…

This episode of The Chain features a live panel discussion moderated by Erica Ollmann Saphire, PhD of La Jolla Institute for Immunology. Expert panelists from academia and government assess the COVID-19 antibody and vaccine development thus far, including what did and did not go well during the pandemic. They also look towards the future and the ro…

The Center for Structural Genomics of Infectious Diseases at Northwestern University was prepared for COVID-19 long before the United States economy shut down. Now over a year since COVID-19 was first recorded in the U.S., co-director Dr. Karla Satchell speaks with The Chain about the role of structural genomics in preparing for disease outbreak an…

Linoleic acid is an essential free fatty acid in the human body and its metabolic pathway is central to immune regulation and inflammation – which are also key symptoms in COVID-19. Using cryo-electron microscopy, Christine Toelzer’s research identified linoleic acid bound to a hydrophobic pocket of the SARS-CoV-2 glycoprotein. Christine shares her…

In this episode we talk with Dennis Karthaus of IBA Lifesciences about his early science interests and pursing his PhD. His passion for marine biology eventually led him on a path to study biotechnology, where he now focuses on protein expression and purification. Specifically, tag-based purification that can help researchers increase lab productiv…

In a roundtable discussion, three experts bring perspectives on different methods for generating antibodies, including generating antibodies from naive libraries, patients, and immunizations. They discuss how the COVID-19 pandemic has highlighted the advantages of refocusing on infectious disease research. As well as the importance of having ready …

The purification requirements in the biopharmaceutical industry will be even more demanding in the coming years due to increased awareness of product-related impurities like oligomers, variants, positional isomers, and glycoforms. These impurities need to be separated from the final product. Dr. Raja Ghosh’s work focuses on the design and developme…

On this episode of The Chain, Dr. Willem Overwijk shares his personal experience of his recent transition from academia to industry, and the differences between the two. Dr. Overwijk moved to industry, in part, to follow his research interest in a specific molecule that he had been working on since graduate studies: interleukin-2. Thanks to advance…

Dr. Dimiter Dimitrov, Director of the Center for Antibody Therapeutics at the University of Pittsburgh, sits down with The Chain to discuss his research and its relevance to the current pandemic. His work focuses on human VH domains, which in contrast to the animal antibody domains, like llama and shark, may have lower probability of immunogenicity…

Dan Chen returns for the Science Commune segment and speaks with Dr. Peter Marks, Director of the FDA’s Center for Biologics Evaluation and Research (CBER). Dr. Marks reflects on his fortuitous path from academia to industry to government, plus the differences between each area. Dr. Marks explains the research and regulatory role of CBER, especiall…

Christian Klein is a longtime and key member of the protein and antibody community. In this episode, he speaks with Executive Conference Producer, Christina Lingham, on how the field has changed since their first collaboration. Dr. Klein offers an overview of the latest applications of bispecific antibodies, including the latest progress of clinica…

There are no bad ideas in developing bioanalytical testing, says Jim McNally, CSO of BioAgilytix. Not all ideas will work, of course. But he has found that it is the outside-the-box ideas that often turn out to be the solution in challenging assay work. Dr. McNally speaks with The Chain about his background in bioanalytical testing and supporting c…

There are some proteins that still evade scientists in the race for better therapeutics. Some of the most elusive drug targets in cancer research are RAS oncoproteins. In a paper published this July, researchers demonstrated the delivery of an extremely potent pan-RAS-cleaving enzyme, opening the door for the first targeted pan-RAS inhibitor for ca…

Carolyn Bertozzi grew up in a science family with a physicist father. But it was organic chemistry that “clicked” for Carolyn and started her down the path of understanding biology at a molecular level. Daniel Chen and Carolyn Bertozzi discuss her work in glycobiology. Bertozzi’s research finds that glycosylation has consequences in immune modulati…

What was science like before the shift to big data technology? How did biologists learn about cells before we could do high throughput gene analysis? What we can learn about how to problem solve from those who helped get us to where we are today? In this Science Commune episode, Dr. Rik Derynck helps us answer those questions by sharing his stories…

In this Science Commune segment, Dr. Daniel Chen and Dr. Pablo Umaña discuss what it means to be both a scientist and an engineer while utilizing principles from both disciplines to solve problems and advance innovation.Cambridge Healthtech Institute által

Dr. David Wood is working on novel technology with self-cleaving tags, but he knows the importance of failure in the grand scheme of success, as well as mentorship, making your own way, and going your own speed.Cambridge Healthtech Institute által

Sara Mangsbo is Entrepreneur of the Year, but her journey to success is much more than one title or one year. She shares the process and her biggest takeaways of building a company that is developing novel immunotherapies to fight cancer.PEGS Summit által